Monitor year-end 2026 for initial interim efficacy and safety data from the IgAN cohort — this is the next binary catalyst for vensobafusp alfa in renal disease. The FSGS expansion adds pipeline optionality but is early-stage.
Price Chart
Executive Summary
Jasper Therapeutics completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study of vensobafusp alfa (KP104), with initial interim data expected by year-end 2026. The company also accelerated an expansion cohort in focal segmental glomerulosclerosis (FSGS), with first dosing anticipated in Q1 2027. This is a routine operational milestone for a clinical-stage biotech — no financial data or efficacy results were released.
Key Facts
- Completed enrollment of 18 IgAN patients in Stage 1 of Phase 2 basket study of vensobafusp alfa (KP104).
- Initial interim data from IgAN cohort expected by year-end 2026.
- Expansion cohort in FSGS announced; first patient dosing anticipated in Q1 2027.
- Study evaluates Q2W, Q4W, and Q8W subcutaneous maintenance dosing regimens (n=6 each).
- Study is conducted in China to provide proof-of-concept in renal diseases including IgAN, C3G, and FSGS.
Financial Impact
No financial data reported in this filing.
Risk Factors
- Interim data from a small 18-patient open-label study may not predict later-stage trial outcomes.
- No financial data or cash runway update provided; capital needs remain opaque.
- Competitive landscape includes approved IgAN therapies and other complement inhibitors in development.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-109587 |
| Document: ea030865701ex99-1.htm | 0001213900-26-109587 |
| Document: 0001213900-26-109587-index-headers.html | 0001213900-26-109587 |
| Document: 0001213900-26-109587-index.html | 0001213900-26-109587 |
| Document: 0001213900-26-109587.txt | 0001213900-26-109587 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5054 (−0.90%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5054 (+1.10%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5054 (−5.02%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5054 (+5.00%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5054 (+5.02%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5054 (+17.03%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5054 (−36.03%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5054 (−19.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers